[CAS NO. 147657-22-5] Calcipotriol monohydrate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [147657-22-5]

Catalog

HY-10001A

Brand

MCE

CAS

147657-22-5

DESCRIPTION [147657-22-5]

Overview

MDL	-
Molecular Weight	430.62
Molecular Formula	C27H42O4
SMILES	O[C@H](C/1=C)C[C@H](O)CC1=C\C=C2[C@@](CC[C@@H]3[C@@H](/C=C/[C@@H](O)C4CC4)C)([H])[C@]3(C)CCC\2.O

For research use only. We do not sell to patients.

10 Publications Citing Use of MCE

Summary

Calcipotriol monohydrate is a synthetic VitD3 analogue with a high affinity for the vitamin D receptor.

IC50 & Target

vitamin D receptor ^[1]

In Vitro

When NHEK cells are not stimulated with IL-17A or IL-22, Calcipotriol slightly enhances (0.2 nM) IL-8 mRNA expression or has no effect (2-20 nM). The addition of IL-17A and IL-22 markedly increased the mRNA expression of IL-8, confirming our previous study. This enhanced IL-8 mRNA expression is suppressed by Calcipotriol at 2, 20 and 40 nM in a dose dependent manner ^[1] . Treatment of natural killer (NK) cells with drugs modulates their expression of NK cytotoxicity receptors or KIR. Human NK cells are pre-treated with 100, 10 or 1 ng/mL of 1,25(OH) ₂ D ₃ , Calcipotriol or FTY720 for 4 h. All three concentrations of 1,25(OH) ₂ D ₃ , Calcipotriol and FTY720 significantly up-regulate the expression of NKp30 on the surface of NK cells after 4 h incubation ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

One out of the 32 animals in each of the groups has died, except for the Diclofenac plus DFMO plus Calcipotriol group, where all animals survived. Survival is equally distributed between the groups. The weight gain is significantly smaller in the groups treated with Diclofenac plus Calcipotriol (p=0.018) and Diclofenac plus DFMO plus Calcipotriol (p=0.002) compare with placebo (linear regression model) ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00243464	LEO Pharma	Psoriasis of Scalp	September 2005	Phase 3
NCT02858713	Odense University Hospital	Adherence	January 9, 2017	Phase 4
NCT04839731	Carilion Clinic	Squamous Cell Carcinoma	April 14, 2021	Early Phase 1
NCT00670241	LEO Pharma	Psoriasis Vulgaris	April 2008	Phase 3
NCT01043224	LEO Pharma	Psoriasis Vulgaris	January 2010	Phase 1
NCT01139580	Stiefel, a GSK Company\|GlaxoSmithKline	Psoriasis	May 2010	Phase 3
NCT02976727	Dong-A University	Actinic Dermatosis	May 2014	Phase 1
NCT01745133	Leon Kircik, M.D.\|Stiefel, a GSK Company\|Derm Research, PLLC	Psoriasis	January 2013	Phase 4
NCT00437255	Galderma R&D	Plaque Psoriasis	August 2006	Phase 4
NCT00796211	Zalicus	Plaque Psoriasis	November 2008	Phase 2
NCT03093805	Children´s Hospital Medical Center, Cincinnati	Graft Vs Host Disease	March 15, 2017	Not Applicable
NCT00704262	LEO Pharma	Psoriasis Vulgaris	May 2008	Phase 2
NCT01368887	DermiPsor, Ltd.	Psoriasis	April 2013	Phase 2
NCT01268527	Eisai Limited\|Eisai Inc.	Psoriasis Vulgaris	March 15, 2010	Phase 2
NCT00875277	LEO Pharma	Psoriasis Vulgaris	April 2009	Phase 2
NCT04555707	Derm Research, PLLC	Psoriasis	June 24, 2020	Phase 4
NCT00216827	LEO Pharma	Psoriasis of Scalp	November 2004	Phase 3
NCT04329221	Massachusetts General Hospital\|Washington University School of Medicine	Cutaneous Squamous Cell Carcinoma\|Actinic Keratoses\|Skin Cancer\|Organ Transplant Recipients\|Immunotherapy	January 1, 2023	Phase 2
NCT03122353	Tolmar Inc.	Scalp Psoriasis	April 11, 2017	Phase 1
NCT02411643	Northwestern University	Morphea\|Localized Scleroderma	March 2015	Early Phase 1
NCT01195831	LEO Pharma	Scalp Psoriasis	September 2010	Phase 3
NCT03448081	Sienna Biopharmaceuticals\|Sienna Labs	Pruritus\|Psoriasis	February 12, 2018	Phase 2
NCT00248456	LEO Pharma	Psoriasis Vulgaris	October 2005	Phase 4
NCT01105286	LEO Pharma	Psoriasis Vulgaris	April 2010	Phase 1
NCT02019355	Washington University School of Medicine	Actinic Keratosis	October 2013	Early Phase 1
NCT01536938	LEO Pharma	Psoriasis Vulgaris	May 2012	Phase 2
NCT00445250	Rabin Medical Center	Radiodermatitis		Phase 2
NCT03848806	Haus Bioceuticals	Psoriasis	February 29, 2016	Phase 2
NCT02132936	LEO Pharma	Psoriasis Vulgaris	June 2014	Phase 3
NCT03020199	Novartis Pharmaceuticals\|Novartis	Plaque Psoriasis	March 27, 2017	Phase 4
NCT03392311	Guangdong Provincial Hospital of Traditional Chinese Medicine	Mesenchymal Stromal Cells\|Psoriasis\|Drug Effect\|Drug Toxicity	August 17, 2019	Phase 1\|Phase 2
NCT04275024	Guangdong Provincial Hospital of Traditional Chinese Medicine	Mesenchymal Stromal Cells\|Psoriasis\|Drug Effect\|Drug Toxicity	April 1, 2020	Not Applicable
NCT01105234	LEO Pharma	Irritation	April 2010	Phase 1
NCT01422434	LEO Pharma\|Quintiles, Inc.	Psoriasis	July 2011	Phase 3
NCT01563068	Mayne Pharma International Pty Ltd\|GlaxoSmithKline	Psoriasis	April 2012	Phase 1
NCT03596073	Massachusetts General Hospital	Breast Cancer	November 7, 2018	Phase 1
NCT01837576	LEO Pharma	Psoriasis Vulgaris	April 2013	Phase 1
NCT05174598	Cadila Pharnmaceuticals\|Lipidor AB, Svärdvägen 13 SE-182 33 Danderyd, Sweden	Mild to Moderate Plaque Psoriasis	October 3, 2018	Phase 3
NCT00216879	LEO Pharma	Psoriasis of Scalp	February 2005	Phase 3
NCT01445886	Yin-ku Lin\|Chang Gung University\|Chang Gung Memorial Hospital	Nail Psoriasis	January 2011	Phase 2\|Phase 3
NCT02733874	First Hospital of China Medical University	Psoriasis	April 2015	Phase 4
NCT02644954	Postgraduate Institute of Medical Education and Research	Psoriasis	January 2016	Phase 3
NCT00691002	LEO Pharma	Psoriasis Vulgaris	May 2008	Phase 3
NCT01646567	TetraLogic Pharmaceuticals	Plaque Type Psoriasis	September 2012	Phase 1
NCT00705900	NeoStrata Company, Inc.	Chronic Plaque Psoriasis	January 2007	Not Applicable
NCT02416258	LEO Pharma	Skin and Connective Tissue Diseases	April 2015	Phase 2
NCT01763424	Isfahan University of Medical Sciences	Psoriasis	July 2011	Phase 2\|Phase 3
NCT00625326	Deltanoid Pharmaceuticals	Plaque-type Psoriasis	January 2008	Phase 2
NCT03069144	Haus Bioceuticals	Psoriasis\|Psoriasis Vulgaris	January 6, 2012	Phase 1\|Phase 2
NCT00392067	LEO Pharma	Atopic Dermatitis	October 2006	Phase 2
NCT05416320	Wake Forest University Health Sciences	Central Centrifugal Cicatricial Alopecia	January 2023	Early Phase 1
NCT01297166	LEO Pharma	Psoriasis Vulgaris	February 2011	Phase 1
NCT00404196	LEO Pharma	Hand Eczema	October 2006	Phase 2
NCT00578370	ISDIN	Psoriasis	November 2007	Phase 1\|Phase 2
NCT03996252	Tulane University\|Mayne Pharma International Pty Ltd	Actinic Keratoses	July 1, 2019	Early Phase 1
NCT01694433	University of California, Los Angeles\|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Acne Vulgaris	February 2013	Phase 2\|Phase 3
NCT02191007	Xijing Hospital	Psoriasis	November 2013	Not Applicable
NCT00437619	Hoffmann-La Roche	Psoriasis	February 2007	Phase 4
NCT02680717	Medical College of Wisconsin\|Mayo Clinic\|Seattle Children´s Hospital\|University of Toronto	Scleroderma	March 2016	Phase 1
NCT00263718	LEO Pharma	Psoriasis Vulgaris	December 2005	Phase 2
NCT01536886	LEO Pharma	Psoriasis Vulgaris	May 2012	Phase 2
NCT00817219	LEO Pharma	Psoriasis Vulgaris	July 2009	Phase 2
NCT05381597	Boston University	Superficial Basal Cell Carcinoma\|Squamous Cell Carcinoma in Situ	October 15, 2022	Phase 2\|Phase 3
NCT03234673	Assiut University	Vitiligo Vulgaris	August 2017	Phase 1
NCT01466478	LEO Pharma	Psoriasis Vulgaris	November 2011	Phase 1
NCT00640822	LEO Pharma	Psoriasis Vulgaris	February 2008	Phase 3
NCT02878382	University of Sao Paulo	Actinic Keratosis	October 2016	Not Applicable
NCT01188928	LEO Pharma	Psoriasis Vulgaris	September 2010	Phase 3
NCT04380597	Angeles Florez\|Complejo Hospitalario Universitario de Pontevedra	Nail Psoriasis	March 26, 2019
NCT03847441	Aswan University Hospital	Alopecia Areata	October 1, 2017	Not Applicable
NCT01582932	Mayne Pharma International Pty Ltd\|GlaxoSmithKline	Psoriasis	April 2013	Phase 1
NCT00358384	GlaxoSmithKline	Psoriasis	September 26, 2005	Phase 1
NCT04642287	Massachusetts General Hospital\|Washington University School of Medicine	Immunotherapy\|Cutaneous Squamous Cell Carcinoma\|Actinic Keratoses\|Organ Transplant Recipients\|Skin Cancer	January 2023	Phase 2
NCT00820950	Incyte Corporation	Psoriasis	May 31, 2007	Phase 2
NCT03399526	Bayer	Psoriasis	February 11, 2013	Phase 1
NCT00216840	LEO Pharma	Psoriasis of Scalp	December 2004	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, protect from light, stored under nitrogen

* The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility

In Vitro:

Ethanol : 100 mg/mL ( 232.22 mM ; Need ultrasonic)

DMSO : 100 mg/mL ( 232.22 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3222 mL	11.6112 mL	23.2223 mL
5 mM	0.4644 mL	2.3222 mL	4.6445 mL
10 mM	0.2322 mL	1.1611 mL	2.3222 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: 5 mg/mL (11.61 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 5 mg/mL (11.61 mM); Clear solution
3.

Add each solvent one by one: 10% EtOH >> 90% corn oil

Solubility: ≥ 5 mg/mL (11.61 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.81 mM); Clear solution
5.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.81 mM); Clear solution
6.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.81 mM); Clear solution
7.

Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline

Solubility: 2.5 mg/mL (5.81 mM); Suspended solution; Need ultrasonic
8.

Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.81 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-1-[(1R,2E,4S)-4-cyclopropyl-4-hydroxy-1-methyl-2-buten-1-yl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, hydrate (1:1), (1R,3S,5Z)-

9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, monohydrate, (1α,3β,5Z,7E,22E,24S)-

Calcipotriol monohydrate